Related Experiment Video

Updated: Apr 6, 2026

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

3.0K

The P275A Polymorphism in the Macrophage Scavenger Receptor 1 Gene and Prostate Cancer Risk: a Meta-Analysis

Qiao-Xia Zhou1, Jian-Qiu Tang, Fen Zhao

  • 1West China School of Preclinical and Forensic Medicine, Sichuan University, Sichuan Province, China

Asian Pacific Journal of Cancer Prevention : APJCP
|July 31, 2015
PubMed
Abstract

Insights

This meta-analysis found no significant association between the MSR1 P275A polymorphism and prostate cancer risk. The macrophage scavenger receptor 1 (MSR1) P275A variant is unlikely to be a contributing factor for developing prostate cancer.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Inconclusive evidence links the macrophage scavenger receptor 1 (MSR1) P275A polymorphism to prostate cancer (PCa) risk.
  • Previous studies show conflicting results regarding the MSR1 P275A polymorphism's role in PCa development.

Purpose of the Study:

  • To comprehensively evaluate the genetic risk associated with the MSR1 P275A polymorphism in prostate cancer.
  • To clarify the association between the MSR1 P275A polymorphism and prostate cancer susceptibility through a meta-analysis.

Main Methods:

  • A systematic literature search was conducted across multiple databases (PubMed, Medline, Embase, etc.) up to April 27, 2015.
  • Meta-analysis included 12 case-control studies comprising 5,017 cases and 4,869 controls.
  • Statistical analyses were performed using Revman 5.2 and STATA 10.1 software.

Main Results:

  • No significant association was found between the MSR1 P275A polymorphism and PCa risk across various genetic models (dominant, co-dominant, recessive, over-dominant, allelic).
  • Stratified analyses by ethnicity (white, yellow, black, mixed) and study design (population-based, hospital-based) also revealed no significant associations.
  • Pooled analysis of 5,017 cases and 4,869 controls did not support a link between the MSR1 P275A polymorphism and prostate cancer.

Conclusions:

  • The P275A polymorphism in the macrophage scavenger receptor 1 (MSR1) gene is unlikely to be a risk factor for prostate cancer.
  • This comprehensive meta-analysis suggests that the MSR1 P275A variant does not contribute significantly to prostate cancer development.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K
An In vitro Model to Study Heterogeneity of Human Macrophage Differentiation and Polarization07:42

An In vitro Model to Study Heterogeneity of Human Macrophage Differentiation and Polarization

Published on: June 12, 2013

19.7K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
131
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
114